ERBB2 and non-small cell lung carcinoma: Eight driver genes, EGFR, ROS1, MET, RET, ALK, ERBB2, KRAS, and BRAF, are recommended by the NCCN guideline to inform the selection of effective targeted therapies for NSCLC patients.